Experience
Mylan Pharmaceuticals Inc. et al.
Biogen MA Inc. et al.
Represented patent owner Biogen in inter partes review (IPR) challenge related to Tecfidera® (dimethyl fumarate) for the treatment of multiple sclerosis.
Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al., IPR2018-01403, PTAB, Judges Chagnon, Harlow, Snedden
Sequenom, Inc. et al
Abbott Laboratories v. Teva Pharmaceuticals USA, Inc.
Abbott Laboratories
Sandoz, Inc. et al v. Pharmacyclics LLC
Pharmacyclics LLC; Janssen Biotech, Inc.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Aerin Medical Inc. et al. v. Neurent Medical Inc. et al.
Aerin Medical Inc. et al.
AbbVie Inc.
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
American Regent, Inc.
Grünenthal GmbH et al. v. Alvogen Pine Brook, Inc. et al.
Grünenthal GmbH et al.
Sandoz Inc. v. Boehringer Ingelheim International GmbH et al.
Boehringer Ingelheim International GmbH et al.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.